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Migration of activated regulatory T (Treg) cells to
inflamed tissue is crucial for their immune-modulatory
function.Whilemetabolic reprogramming during Treg
cell differentiation has been extensively studied, the
bioenergetics of Treg cell trafficking remains unde-
fined. We have investigated the metabolic demands
of migrating Treg cells in vitro and in vivo. We show
that glycolysis was instrumental for their migration
and was initiated by pro-migratory stimuli via a
PI3K-mTORC2-mediated pathway culminating in
induction of the enzyme glucokinase (GCK). Subse-
quently, GCK promoted cytoskeletal rearrangements
by associating with actin. Treg cells lacking this
pathway were functionally suppressive but failed to
migrate to skin allografts and inhibit rejection.
Similarly, human carriers of a loss-of-function GCK
regulatory protein gene—leading to increased GCK
activity—had reduced numbers of circulating Treg
cells. These cells displayed enhanced migratory
activity but similar suppressive function, while
conventional T cells were unaffected. Thus, GCK-
dependent glycolysis regulates Treg cell migration.
INTRODUCTION
Thymic regulatory T (Treg) cells, defined as CD4+CD25+Foxp3+
T cells, are instrumental for the maintenance of tolerance to
self-antigens. Treg cells exert their immunomodulatory role by
localizing to both lymphoid and non-lymphoid tissue.Immunity 47, 875–889, Novem
This is an open access article under the CC BY-NA rapid accumulation of Treg cells relative to T effector (Teff)
cells—in which more than 30% of the infiltrating lymphocytes
are Treg cells—occurs in inflamed tissue during immune regula-
tion (Tang et al., 2012). By contrast, the small proportion of these
cells in the peripheral blood (2%–5%) further emphasizes their
remarkable migratory ability.
The bioenergetics of Teff and Treg cell function, expansion,
and survival has been extensively studied. Teff and Treg cells
require distinct metabolic programs to support their survival
and differentiation: T helper (Th)1, Th2, and Th17 cells express
high surface amounts of glucose transporter Glut1 and are highly
glycolytic, whereas Treg cells express low amounts of Glut1 and
have high lipid oxidation rates in vitro (Michalek et al., 2011). The
mammalian target of rapamycin (mTOR) plays a key role in cell
fate decision by regulating T cell metabolic responses. T cell
activation stimulates mTOR to increase glycolysis and diminish
lipid oxidation (Wieman et al., 2007). In contrast, blockade of
glycolysis promotes generation of Treg cells, and this occurs
via inhibition of mTOR-mediated induction of the transcription
factor hypoxia-inducible factor (HIF1a) (Dang et al., 2011; Shi
et al., 2011). However, while Treg cells mainly rely upon an oxida-
tive metabolism, some specific functions can be dependent on a
selective switch to glycolysis. Their metabolism appears to oscil-
late from mTOR-dependent and -independent pathways in
response to environmental cues (Procaccini et al., 2010). Toll-
like receptor (TLR) signals promote Treg cell proliferation via
mTORC1 signaling, glycolysis, and Glut1 upregulation, but these
signals also reduce their suppressive ability (Gerriets et al., 2016).
Despite motility being likely the most energy-consuming
cellular activity (Bernstein and Bamburg, 2003), the metabolic
demands for T cell migration have been only partly investigated.
We have shown that Teff cell migration relies upon the glycolytic
pathway (Haas et al., 2015). However, the metabolic program(s)
that fuel Treg cell migration remain unknown.ber 21, 2017 ª 2017 The Author(s). Published by Elsevier Inc. 875
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Integrins such as LFA-1 play a key role T cell trafficking; in addi-
tion, signals generated by the co-stimulatory or the co-inhibitory
receptors CD28 and CTLA-4, respectively, actively participate
in the regulation of T cell trafficking. In the lymph nodes, CD28
activation promotes memory T cell egression and migration to
target tissue (Jain et al., 2013; Mirenda et al., 2007), while
CTLA-4 antagonizes CD28 pro-migratory signals (Mirenda
et al., 2007). Effector Treg cell migration is also regulated by
CD28 signals (M€uller et al., 2008). Importantly, costimulatory
receptors also regulate T cell metabolic reprogramming to
enhanced glycolysis (Frauwirth et al., 2002; Parry et al., 2005),
suggesting that glycolysis and migration might be tightly linked
in Treg cells.
By comparing LFA-1- and CD28-mediated pro-migratory
signals as a working model, we have investigated the bioener-
getics of migrating Treg cells in vitro and in vivo. We here define
a specific pathway of metabolic reprogramming sustaining Treg
cell migration both in mice and humans.
RESULTS
Engagement of the Glycolytic Pathway Is Required for
Treg Cell Migration
Given that Treg cells display high lipid oxidation, we first tested
the hypothesis that ex vivo expanded thymic Treg cell migration
may require fatty acid oxidation (FAO) by exposing the cells to
acetyl-CoA carboxylase (ACC) inhibitor Etomoxir (Figures S1B
and S1C). This pre-treatment did not affect Treg cell transendo-
thelial migration (TEM) or chemotaxis in vitro (Figures 1A, 1D, and
1E, respectively, and S1A–S1E) or migration to inflamed perito-
neum in vivo (Figures 1F and 1G).
We subsequently explored the possibility that, like conventional
T cells (Tconv), Treg cells utilize glycolysis for migration, by
inhibiting this pathway with the glucose analog 2-deoxyglucose
(2-DG). Treg cells exposed to 2-DG migrated inefficiently both
in vitro (Figures 1B, 1D, 1E, S1D, and S1E) and in vivo (Figures
1H and 1I). In addition to extensive washing after exposure to
the drugs, the inhibition of Treg cell chemotaxis excludes indirect
effects of the drugs on the endothelium in these conditions. In
contrast, activation of glycolysis using metformin, which stimu-
lates glycolysis via AMP kinase, increased Treg cell motility (Fig-
ures 1C–1E, S1D, and S1E) and trafficking (Figures 1J and 1K).
None of the drugs affected expression of migration-relevant
receptors or viability at the doses used (Figures S1F and S1G).
To confirm that the effect of each of these compounds is retained
once in vitro treated T cells are injected into recipient mice, TregFigure 1. Glycolysis Fuels Treg Cell Migration
(A–E)Ex vivo expanded Treg cells pre-treated with the indicated drugs or vehicle for
syngeneic EC monolayers (A–C) or in response to chemokine CCL22 through bar
migrated cells after 24 hr (A–C, n = 4, N = 2) or at the indicated time points (D, n =
migration by spontaneous migration measured at 6 hr in two experiments of identic
(F–K) Drug- or vehicle-treated Treg cells labeled with PKH26 were injected i.v. into
from the indicated tissues after 24 hr and analyzed by flow cytometry. Represent
number of labeled cells recovered in 4 animals ± SD is shown in (G), (I), and (K) (
(L and M) Representative histograms from 3 independent experiments of Treg
fragments (Fc) for 45 min and then re-suspended in medium containing the gluc
(N and O) ECAR of ICAM-1- (N) or CCL22-stimulated (O) cells was measured by a
Recombinant molecules and glucose were added at the time points indicated (±
*p < 0.05, **p < 0.005. Please see also Figure S1.cells were exposed to the various drugs for 4 hr, extensively
washed, and incubated in culture medium alone for a further
16 hr. The effects on drug-treated cell motility were still apparent
after the prolonged incubation without the compounds (Figures
S1I–S1N).
To confirm the induction of the glycolytic pathway by pro-
migratory stimuli, we subsequently tested the effect of engage-
ment of the adhesion molecule integrin LFA-1, a key mediator
of T cell migration, on aerobic glycolysis in Treg cells. Immobilized
or antibody-ligated recombinant mouse ICAM-1 (rICAM-1), a
ligand of LFA-1, was used for this purpose.
First we estimated LFA-1-induced glucose uptake using
the glucose analog 6-[N-(7-nitrobemz-2-oxa-1,3-diazol-4-yl)
amino]-2-deoxyglucose (6-NBDG), which cannot be phosphory-
lated by hexokinases and accumulates in the cytoplasm in its
fluorescent form. Treg cells were stimulated with plastic-bound
rICAM-1 or human IgG Fc fragments (control) and 6-NBDG
uptake was measured 30 min later by flow cytometry. As shown
in Figures 1L and 1M, LFA-1 stimulation significantly increased
6-NBDG uptake.
Second, we measured the effects of LFA-1 engagement or
exposure to the chemokine CCL22 (CCR4 ligand) on the extra-
cellular acidification rate (ECAR), which quantifies proton pro-
duction as a surrogate for lactate production and thus reflects
overall glycolytic flux. ECAR increase upon glucose supply was
significantly enhanced following LFA-1 or CCR4 (Figures 1N
and 1O) stimulation. Meanwhile, the oxygen consumption rate
(OCR), a measure of mitochondrial respiration, was not affected
(Figures S1N and S1O).
CD28 and CTLA-4 Regulate Treg Cell Migration through
Modulation of the Glycolytic Pathway
As triggering of LFA-1 by endothelial ICAM-1 is a frequent event
during recirculation—hence difficult to manipulate—to address
the metabolic requirement of Treg cell trafficking in vivo we sub-
sequently focused on the effects CD28 and CTLA-4 (Figure S2A)
costimulatory and coinhibitory signals, which can be delivered
ex vivo with well-characterized reagents (Figure S2B).
First, we confirmed that antibody activation of CD28 en-
hances ex vivo expanded Treg cell TEM (Figure S2C) and
chemotaxis (Figures S2D and S2E) in vitro and migration in vivo
(Figure S2F), without affecting expression of relevant receptors
(Figures S2G and S2H). Also, we observed that while CTLA-4
triggering alone did not affect cell migration, co-ligation with
CD28 abrogated CD28-induced migration (Figures S2C
and S2D).4 hrwere left tomigrate through 3 mm-pore transwells layeredwith IFN-g-treated
e-filter 5 mm-pore transwells (D and E). Results are expressed as percentage of
3) ± SD. The fold increase in migration was calculated by dividing experimental
al design performed in triplicates ± SD.
syngeneic recipients treated with IFN-g i.p. 48 hr earlier. Cells were harvested
ative dot plots from 3 animals are shown in (F), (H), and (J). The mean absolute
N = 1).
cells stimulated with plastic-bound recombinant (r)ICAM-1 or human IgG Fc
ose uptake indicator 6-NBDG for 10 min. The mean MFI ± SD is shown in (M).
n extracellular flux analyzer (Seahorse). Ig Fc or medium was used as a control.
SD n = 5, N = 2).
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Figure 2. Treg Cell Migration Is Regulated by Co-stimulatory Receptors via Induction of Glycolysis
(A and B) Representative histograms from 3 independent experiments of antibody-stimulated Treg cells incubated with 6-NBDG for 10 min prior to analysis.
The non-fluorescent glucose analog 2-DG was used as a negative control. The mean MFI ± SD is shown in (B) (N = 3).
(C) ECAR of antibody-stimulated Treg cells was measured by fluxometry. Antibodies (Ab) and D-glucose were injected at the indicated time points ± SD.
(D–F) ECAR (±SD) was measured in WT or Ctla4/ Treg cells either unstimulated (D) or previously stimulated with recombinant CD80 or Fc fragments for 30 min
(E and F). D-glucose was injected as indicated by the green line.
(legend continued on next page)
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Second, wemeasured the impact of CD28 andCTLA-4 signals
on the glycolytic pathway in Treg cells. CD28 triggering signifi-
cantly increased 6-NBDG uptake (Figures 2A and 2B) and
glycolytic flux (Figure 2C) compared to treatment with an isotype
control and secondary antibodies. In contrast, CTLA-4 stimula-
tion did not affect either glucose uptake or ECAR on its own
but when co-ligated, CTLA-4 signals prevented CD28-induced
glucose uptake and ECAR increase. The oxygen consumption
rate (OCR) was not affected by triggering of either costimulatory
receptor (Figures S2I and S2J).
We further explored the link between costimulatory signals and
metabolic regulation of motility by analyzing the metabolic activ-
ity and migration of Ctla4/ Treg cells. In these experiments we
used as stimulator recombinant (r)CD80, a ligand shared by
CD28 and CTLA-4. Compared to WT Treg cells, Ctla4/ cells
displayed a prolonged increase of ECAR in response to glucose
(Figure 2D)—even taking into account a higher acidification base-
line. As expected, the ECAR of WT Treg cells activated with
recombinant CD80 remained unchanged, due to simultaneous
CD28 and CTLA-4 engagement (Figure 2E), while Ctla4/ cells
further increased their glycolytic response to glucose addition
(Figure 2F). Despite the fact that Ctla4/ cell OCR was sponta-
neously higher than that of their WT counterparts, it was not
affected by either CD28 or CTLA-4 signals (Figure S2K).
In parallel, we tested TEM by rCD80-stimulated Ctla4/ Treg
cells through IFN-g-activated syngeneic EC. As shown in Fig-
ure 2G,Ctla4/ Treg cell stimulated with recombinant CD80 dis-
played enhanced migration through EC while WT Treg cells did
not respond to such stimulation, supporting the conclusion that
CTLA-4 signals inhibit CD28-induced glycolysis and migration.
To investigate whether control of Treg cell migration by CD28
andCTLA-4 occurs viamodulation of glycolysis, we analyzed the
effect of CD28 and/or CTLA-4 stimulation during TEM in
glucose-depleted medium. As shown in Figure 2H, glucose
depletion prevented the increase in motility induced by CD28
signals. The results were not influenced by cell distress associ-
ated with glucose deprivation as baseline migration remained
similar in both glucose-sufficient and -deficient conditions.
In vivo, the CD28-glycolysis-migration axis was analyzed by
monitoring 6-NBDG uptake by CD28-stimulated migrating Treg
cells. To this aim, we used a tissue infiltration model in which
the ability of Treg cells injected in the peritoneal cavity to infiltrate
the peritoneal membrane is quantified (Mirenda et al., 2007). This
model was chosen because 6-NBDG fluorescence is rapidly lost
with time, making it technically impossible to track T cells trans-
ferred intravenously long-term. Treg cells were labeled with
PKH26 (red fluorescence) and then underwent CD28 ligation
with or without CTLA-4 triggering, or received isotype-matched
and secondary antibodies as a control prior to i.p. injection in(G) Migration of rCD80- or Fc-stimulated Ctla4/ and WT Treg cells through
percentage of migrated cells at 24 hr ± SD n = 3, N = 4.
(H) Migration of antibody-stimulated Treg cells re-suspended in either gluco
EC monolayers, expressed as percentage of migrated cells after 24 hr ± SD (n =
(K) Antibody-stimulated Treg cells labeled with PKH26 (red) were injected i.p. in
immediately after. Peritoneal membranes were removed 1 hr later, counterstained
number of infiltrating cells and 6-NBDG uptake by the infiltrating cells. Representa
of cells counted in 10 103 fields from 4 recipients ± SD and the mean total cell flu
and (K), respectively (n = 4, N = 2).
*p < 0.05; **p < 0.01; ***p < 0.005. Please see also Figure S2.syngeneic mice treated with IFN-g 48 hr earlier. 6-NBDG (green
fluorescence) was injected i.p. immediately after the cells, thus
allowing parallel evaluation of tissue infiltration and glucose up-
take by labeled Treg cell in vivo. As shown in Figures 2I–2K,
CD28 activation substantially increased the number of cells
infiltrating the peritoneum and displaying 6-NBDG uptake
(yellow fluorescence), indicating that Treg cell migration directly
correlates with glucose uptake in vivo. Both these effects were
prevented by CTLA-4 co-ligation.
Enhancement of Glycolysis and Migration Requires
PI3K-Akt Activation but Is Independent of mTORC1
CD28 stimulation induces glucose uptake and glycolysis via acti-
vation of the PI3K-Akt signaling pathway (Frauwirth et al., 2002;
Jacobs et al., 2008). PI3K activation by CD28 is instrumental for
the transduction of pro-migratory signals, without affecting
expression of migratory receptors, in conventional T (Tconv)
cells (Jarmin et al., 2008), and inefficient migration of T cells to
the inflammatory site is a feature of Cd80/Cd86/ mice
(Chang et al., 1999). To investigate the role of CD28-induced
activation of the PI3K pathway on Treg cell metabolism and
migration, we isolated Treg cells from Cd28Y170F genetically
targeted mice, which carry a mutation in the cytoplasmic tail of
CD28 that selectively prevents recruitment of PI3K (Okkenhaug
et al., 2001). Cd28Y170F Treg cells display normal development
(Tai et al., 2005) and expression of migration-relevant and other
receptors (Figure S3A).
First, we compared the mobilization and recirculation of WT
and Cd28Y170F Treg cells following i.p. injection of Zymosan.
Activation of innate but not adaptive immunity by this method
has been shown to induce accumulation of Treg cells in the peri-
toneal cavity with a peak 72 hr after injection (Newson et al.,
2014). As shown in Figures 3A and 3B, WT and Cd28Y170F Treg
cells—identified as shown in Figure S3B—increased in the
peripheral blood to similar amounts by 72 hr after Zymosan injec-
tion. However, Cd28Y170F Treg cells did not efficiently migrate to
the peritoneal cavity and lymph nodes, indicative of inadequate
extravasation from the bloodstream. CD28 is likely to be
engaged during interactions with LPS-activated dendritic cells.
The ratio of WT Treg cells in LN and blood and in blood and
peritoneum decreased over time, indicating a LN-to-blood-to-
peritoneum recirculation (Figures 3C and 3D). In contrast, the
distribution of Cd28Y170F Treg cells remained stable, confirming
their impaired recirculation and additionally suggesting that the
increase of these cells in the blood is likely due to passive mobi-
lization from the spleen. Thus, CD28 instructs Treg cell recircula-
tion in response to activation of innate immunity.
We subsequently compared the ECAR of CD28-stimulated
purified Cd28Y170F and WT Treg cells. After glucose addition,syngeneic IFN-g-treated EC monolayers. Results are expressed as mean
se-free or glucose-reconstituted medium through IFN-g-treated syngeneic
3, N = 4).
C57BL/6 mice given IFN-g i.p. 48 hr earlier. 6-NBDG (green) was injected i.p.
with DAPI and imaged bywide-field fluorescencemicroscopy to determine the
tive images from 2 independent experiments are shown in (I). Themean number
orescence of 6-NBDG from 10–12 cells from 3 103 fields ± SD are shown in (J)
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the ECAR increase in CD28-stimulated Cd28Y170F cells was
significantly dampened (Figure 3E), suggesting that PI3K recruit-
ment by CD28 signals is required to efficiently induce glycolysis.
We then analyzed the migratory response to CD28 triggering
by Treg cells isolated and expanded from both WT and
Cd28Y170F mice. As shown in Figures 3F–3J, CD28 stimulation
failed to enhance migration of Cd28Y170F Treg cells in vitro (Fig-
ure 3F) and in vivo (Figures 3G–3J), confirming the pivotal role of
CD28-mediated recruitment of PI3K in enhancing Treg cell
migration.
In most T lymphocytes, mTOR kinase couples upstream PI3K
and Akt to glucose uptake and glycolysis (Chi, 2012; Powell and
Delgoffe, 2010). In Treg cells, CD28 signals induced phosphor-
ylation of themTORC1 target ribosomal protein S6 (Figure S3C),
an event that was prevented by CTLA-4 co-ligation. Rapamicyn
treatment prevented Treg cells entering the cell cycle—as
measured by the expression of the proliferating cell nuclear
antigen (PCNA)—in response to immature cognate DCs and
rIL-2 (Figure S3D), and CD28-induced phosphorylation of
ribosomal protein S6 (Figure S3E). However, rapamycin did
not affect CD28-induced migration in vitro (Figures S3F and
S3G) or in vivo (Figures S3H–S3K), suggesting that CD28
promotes Treg cell migration via mediators downstream of
PI3K other than mTORC1.
Pro-migratory Stimuli InduceMetabolic Reprogramming
We have previously shown that in Tconv cells, activation of
glycolysis during migration occurs via transcriptional and post-
transcriptional regulation of the enzyme Hexokinase (HK)I
(Haas et al., 2015). We therefore analyzed the expression of a
number of glycolytic enzymes by expanded Treg cells 4 hr after
CD28 and CTLA-4 stimulation. CD28 stimulation led to a modest
increase in HKI, Enolase, and Aldolase expression by Treg cells
(Figures 4A and 4B). The most substantial increase was
observed in the expression of the HK isoenzyme glucokinase
(HKIV or GCK), a rate-limiting enzyme key to hepatocyte and
pancreatic beta cell function, whose expression by T cells has
not been previously reported. Concomitant CTLA-4 triggering in-
hibited CD28-induced enzyme expression.
We extended our analysis also to HKII and observed that, like
that of GCK, a substantially enhanced expression of this enzyme
occurred as early as 5min after stimulation not only by CD28 sig-
nals, but also following LFA-1 triggering by recombinant ICAM-1
(Figures 4C, S4A, and S4B), suggesting that both stimuli
enhance enzyme expression also by post-transcriptional
mechanisms.Figure 3. CD28-Induced Migration and Metabolic Reprogramming Req
WT and Cd28Y170F mice received an i.p. injection of Zymosan. Samples were coll
indicated tissues was measured by flow cytometry.
(A) Representative dot plots from 2 independent experiments.
(B) The mean percentage of cells measured in two experiments of identical desi
(C and D) Ratio of cells retrieved in the indicated tissues over time ± SD (n = 3).
(E) ECAR (±SD) of antibody-stimulated Cd28Y170F and WT Treg cells was compa
(F) Migration of antibody-stimulatedCd28Y170F andWT Treg cells through IFN-g-t
cells after 24 hr ± SD. N = 4.
(G–J) Equal numbers of antibody-stimulated PKH26-labeledWT orCd28Y170F Tre
Cells were harvested from the indicated tissues 24 hr later, counter-stained for Fox
experiments are shown in (G) and (I). The bar graphs in (H) and (J) indicate mean
*p < 0.05; **p < 0.01; ***p < 0.005. Please see also Figure S3.We then measured transcription of the GCK, HKI, and HKII
genes, which was indeed increased by LFA-1 or CD28 stimula-
tion (Figures 4D, S4C, and S4D, respectively). As expected,
enzyme induction by CD28 was prevented by CTLA-4 triggering.
In this set of experiments, transcription of the GCK regulatory
protein (GCKR) gene (Figure 4E), a post-transcriptional regulator
which blocks free cytoplasmic GCK (Farrelly et al., 1999), was
also analyzed. Confocal analysis of expression and co-localiza-
tion of GCK and GCKR following CD28 and LFA-1 activation
confirmed that both CD28 and LFA1 stimuli decrease GCKR
expression, concomitant to a substantial increase of GCK avail-
ability (Figures 4F and 4G).
To address the relative contribution of HKII and GCK activity
to their motility, Treg cells were treated with either the GCK
activator AZD1656 (Waring et al., 2012) or with the HKII-selective
inhibitor Clotrimazole (CLT), which inhibits the glycolytic flux and
respiration in CD3 plus CD28-stimulated Tconv cells (Figures
S4E and S4F; van der Windt et al., 2013). GCK activation signif-
icantly enhanced Treg cell migration to the inflamed tissue (Fig-
ure 4H) but did not affect division (Figure 4I). Conversely, CLT
was effective at inhibiting PCNA upregulation by Treg cells
(Figure 4J) in response to allogeneic DCs but did not affect
rICAM-1-mediated induction of glycolysis (Figure 4K) or migra-
tion to inflamed peritoneum in vivo (Figure 4L), implying that
HKII is redundant for Treg cell migration.
mTORC2-Dependent Induction of GCK Expression Is
Required for Treg Cell Migration
The above observations implicate GCK as a key enzyme induced
by both CD28- and LFA-1-mediated signals in migrating Treg
cells. GCK expression in the liver is regulated by the relatively
rapamycin-insensitive mTORC2 (Hagiwara et al., 2012).
Based on this evidence and the observation that CD28-
induced Treg cell trafficking is PI3K dependent but rapamycin
insensitive (Figures 3 and S3), we examined the contribution
of mTORC2 signaling to Treg cell metabolism and migration.
First, we confirmed that CD28 triggering led to mTORC2-
dependent AKT phosphorylation at the serine residue 473 (Fig-
ure 5A). Subsequently, expression of Rictor, an obligatory
component of mTORC2, was prevented in expanded Treg cells
by lentivirus-delivered, specific shRNAs (Figures S5A and S5B).
For comparison we also silenced GCK expression. As a control,
cells were transduced with an empty vector (PLKO.1). Gene
silencing did not affect cell survival (Figures S5C and S5D).
Rictor-depleted Treg cells became unable to upregulate GCK
protein expression following CD28 and LFA-1 stimulationuire PI3K but Not mTORC-1 Activation
ected either before or 72 hr after the injection. The presence of Treg cells in the
gn ± SD.
red using fluxometry. n = 4, N = 2.
reated ECmonolayers. Results are expressed as mean percentage of migrated
g cells were injected i.v. into syngeneic mice treated with IFN-g i.p. 48 hr earlier.
p3, and analyzed by flow cytometry. Representative dot plots of 2 independent
absolute numbers of labeled cells (n = 4, N = 2) ± SD.
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Figure 4. Pro-migratory Stimuli Induce Metabolic Reprogramming of Treg Cells
(A and B) Expression of the indicated enzymes in Treg cells was measured 4 hr after antibody stimulation by western blotting. In (B) the mean relative expression
measured by densitometric analysis in 3 independent experiments ± SD is shown.
(C) Expression of the indicated enzymes by CD28- or LFA-1-stimulated Treg cells measured by western blotting at the indicated time points.
(D–G) Relative mRNA expression of GCK (D) and GCKR (E) and cellular protein expression (F and G) by antibody-stimulated Treg cells wasmeasured by RT-PCR
and confocal microscopy, respectively. In (G) the mean MFI ± SEM measured using ImageJ software is shown. N = 3. Scale bar 20 mm.
(H) AZD1656 (GCK activator, 1 mM) and vehicle-treated Treg cells (2 hr in insulin-free medium) were labeled with different intravital fluorescent dyes, and
co-injected into syngeneic recipients that had received IFN-g i.p. 48 hr earlier. Cells were recovered from the peritoneum or spleen after 24 hr and analyzed by
flow cytometry. Representative dot plots from 2 independent experiments are shown. The bar graphs indicate mean absolute number of labeled cells
retrieved ± SD (n = 4, N = 2).
(legend continued on next page)
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(Figure 5B), suggesting that this event was mTORC2 depen-
dent. Confocal analysis of Rictor-deficient cells confirmed their
failure to upregulate GCK expression in response to the pro-
migratory signals compared to mock-transduced cells (Figures
5C and 5D). Furthermore, Treg cells lacking mTORC2 activity
did not downregulate GCKR expression (Figure 5E). The ability
of Rictor- and GCK-shRNA silenced Treg cells to enhance the
glycolytic flux upon CD28 or LFA-1 stimulation was also signif-
icantly impaired compared to mock-transduced cells (Fig-
ure 5F). A glycolysis stress test showed that, although they
were unable to increase the glycolytic flux in response to
CD28 and LFA-1 signals, both Rictor- and GCK-deficient
Treg cells maintained a basal and maximal glycolytic response
(Figures 5G and 5H), while their glycolytic reserve was signifi-
cantly impaired (Figure 5I).
Despite these metabolic alterations, the suppressive and
proliferative capacity of Rictor- and GCK-deficient Treg cells
were similar to those of their mock-transduced counterpart
(Figures S6A–S6C), indicating that this pathwaywas not required
for these functions.
To assess whether the metabolic impairment resulted in
alteration of migratory responses, differentially labeled cells
transduced with Rictor- or GCK-specific or control shRNAs
underwent CD28 or IsC antibody ligation prior to co-injection in
syngeneic recipients, which had received a i.p. injection of
IFN-g 48 hr earlier. Their migration to the peritoneal cavity,
spleen, and LN was compared 16 hr later. Both Rictor- and
GCK-depleted Treg cell migration to the inflammatory site was
severely impaired compared to that by mock-transduced cells
and was not enhanced by CD28 activation (Figures 6A and
6B). In addition, although similar numbers of cells were injected,
significantly lower numbers of GCK-deficient Treg cells were
retrieved in the spleen—where early migration does not require
active mechanisms—compared with Rictor-deficient or mock-
transduced cells (Figures 6C and 6D). We hypothesized that
the severe impairment of GCK-deficient Treg cell cytoskeleton
might render them unable to squeeze through the pulmonary
capillaries and leave the lungs following injection in the venous
blood. Indeed, the ratio of GCK-deficient cells retrieved in the
lung and the spleen was significantly increased compared to
that of control cells independently of CD28 activation (Figure 6E).
In addition, although inefficiently compared to mock-transduced
cells, shGCK Treg cells were still capable of migrating through
pores with a 5 mm diameter in chemotaxis assays, but failed to
migrate through 3 mm pores (Figures 6F and 6G), suggesting a
severe impairment of cytoskeletal function as a consequence
of loss of GCK activity.
In this context, we observed that pro-migratory activity of
CD28 signals was accompanied by intense actin remodeling,(I and J) expression of PCNA by Treg cells stimulated with allogeneic DCs follow
or vehicle alone was measured by flow cytometry. NS, non-stimulated control c
(n = 3, N = 3).
(K) ECAR of Treg cells activated with recombinant ICAM-1 or Fc control. CLT or
(L) CLT- or vehicle-treated Treg cells underwent CD28 or isotype-matched antibo
in syngeneic recipients that had received IFN-g i.p. 48 hr earlier. Cells were rec
cytometry. Representative dot plots from 2 independent experiments are sh
retrieved ± SD (n = 3, N = 2).
*p < 0.05 ***p < 0.005; ****p < 0.001. Please see also Figure S4.which was prevented by CTLA-4 signals (Figures S6D and
S6E). Glycolytic enzymes including GCK interact with actin
(Clarke and Masters, 1975; Murata et al., 1997) to act as a
glycolytic ATP feeder for the ATP-hydrolyzing sodium
pump (Na,K-ATPase), thus generating energy required for
cytoskeletal rearrangements (Jung et al., 2002). We therefore
assessed GCK and Na,K-ATPase localization on the actin
cytoskeleton in CD28- and LFA-1-stimulated Treg cells. First,
we observed that GCK became associated with actin
following CD28 stimulation (Figure S6F). Further, unstimulated
cells displayed reduced F-actin and GCK expression, which
appeared associated with the cytoskeleton (Figures S6G–
S6I). Similarly, ATPase expression was low and only partially
co-localized with GCK (Figures S6G, S6H, and S6J). Stimula-
tion of CD28 or ICAM led to intense F-actin formation and
upregulation of associated GCK and increased expression of
the Na,K-ATPase, which also associated with GCK (Figures
S6G–S6I). As expected, since shRictor-silenced Treg cells
produce less GCK, the amount of co-localization with F-actin
was also lower.
To further confirm the selective impact of Rictor and GCK
deficiency on Treg cell motility, we finally compared the ability
of adoptively transferred (107/mouse) control, Rictor-deficient,
or GCK-deficient cells to delay rejection of fully allogeneic skin
grafts. As expected, Rictor- and GCK-depleted Treg cells failed
to prolong graft survival (Figure 6H) as they did not localize in the
graft (Figures 6I and 6J) compared to mock-transduced cells. In
line with previous results, fewer GCK-deficient cells were found
also in the spleen.
Human Treg Cells from Homozygous Carriers of a Loss-
of-Function Polymorphism in the GCKR Gene Display
Enhanced Motility
To test the physiological relevance of this pathway in the human
system, we analyzed the number and functional behavior of
circulating Treg cells (defined as CD25hiCD127lo) from carriers
of a loss-of-function polymorphism in the GCKR gene (C to T,
P446L). P446L-GCKR has reduced inhibitory activity toward
GCK and has been associated with decreased fasting plasma
glucose and enhanced triglyceride synthesis (these parameters
measured in our study population are shown in Figures S7A
and S7B) via increased GCK activity in the liver of homozygous
carriers (Beer et al., 2009).
The number of circulating Treg cells was decreased in carriers
of the rare allele 446L of GCKR gene compared to carriers of the
WT allele (Figures 7A, 7B, S7A, and S7B) while other CD4+ T cell
populations were unaffected (Figures 7C–7E). Importantly,
446L-GCKR Treg cells displayed increased chemokine-induced
motility compared to WT-GCKR Treg cells, while Tconv celling treatment with either AZD1656 (I) or Clotrimazole (CLT, 1 mM, 2 hours, J)
ells. Representative histograms from 3 independent experiments are shown.
vehicle as well as other glycolysis-affecting drugs were added as indicated.
dy stimulation, labeled with different intravital fluorescent dyes, and injected i.v.
overed from the peritoneum (P) or spleen (S) after 24 hr and analyzed by flow
own. The column graphs indicate mean absolute number of labeled cells
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Figure 5. mTORC2 Controls Metabolic Reprogramming Induced by Pro-migratory Stimuli
(A) Phosphorylation of AKT at Thr308 and Ser473 in Treg cells activated with CD28- or IsC-antibody ligation was measured by immunoblotting.
(B) Treg cells were virally transfected with Rictor-specific or GCK-specific or non-sense (PLKO.1) sh-RNAs, as described in STAR Methods. Expression of GCK
was measured by immunoblotting 24 hr later.
(C–E) Expression of GCK and GCKR by control or Rictor-deficient Treg cells following CD28 or LFA-1 activation for 45 min. Bar graphs (D and E) show the mean
protein expression (Total cell fluorescence) measured in 3 independent experiments by ImageJ software ± SD. Scale bar, 40 mm.
(F–I) ECAR of CD28- or LFA-1-stimulated Rictor- andGCK-deficient and control T cells wasmeasuredwith an extracellular flux analyzer. A glycolysis stress assay
was performed by adding the indicated compounds at the time points indicated by the green lines. The basal and maximal glycolysis and the glycolytic reserve
are shown in (G), (H), and (I), respectively (±SEM). N = 2.
*p < 0.05 ***p < 0.005; ****p < 0.001. Please see also Figure S5.
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Figure 6. Rictor-Deficient Treg Cells
Display Impaired Motility
(A–E) CD28-stimulated or IsC-treated PLKO.1,
Rictor- or GCK-deficient Treg cells were labeled
with PKH26 and co-injected i.v. with identical
numbers of IsC-treated CFSE-labeled cells in
syngeneic recipients treated with IFN-g 48 hr
earlier. The presence of differently labeled cells in
the indicated organs was assessed by flow cy-
tometry 24 hr later. Representative dot plots from
3 independent experiments are shown on top in
(A), (B), and (C). The bar graphs in (A), (B), and (D)
indicate mean absolute number of labeled Treg
cells recovered in the indicated tissues from 4
different recipients ± SD (N = 3). The bar graph in
(E) shows the ratio of Treg cells recovered in the
lung and the spleen (n = 4) ± SD.
(F and K) Control and ShGCK Treg cell migration
through 5 or 3 mm pore bare-filter transwells in
response to CCL22 (F) or CXCL10 (K). Results are
expressed as percentage of migrated cells at the
indicated time points ± SD (n = 3).
(H–J) BALB/c-derived skin was grafted onto
C57BL/6 recipients who had received mock-
transduced, Rictor- or GCK-depleted Treg cells or
no cells 24 hr earlier. Graft rejection wasmonitored
daily (H). Some grafts were removed 5 days post-
grafting and the presence of fluorescently labeled
Treg cells in the indicated tissue was assessed by
widefield fluorescence microscopy. Representa-
tive images of grafts and spleens from 2 inde-
pendent experiments are shown in (I). The bar
graphs (J) indicate the mean number of labeled
cells detected in at least 10 103 tissue images
from each animal ± SD (n = 8).
*p < 0.05 **p < 0.01; ***p < 0.005. Please see also
Figure S6.migration was unaffected (Figures 7F and 7G). The suppressive
ability and phenotype of P446L-GCKR Treg cells did not signifi-
cantly differ from that of WT-GCKR Treg cells (Figures S7C–
S7H), including expression of CCR7 (Figures 7H and 7I), the
receptor for the chemokines used in the migration assays. In
addition, chemokine-induced molecular events upstream of
GCK activation, including glucose uptake (Figures S7I–S7L)
and AKT phosphorylation at serine 473 (Figures S7M–S7P),
were comparable in 446L- and 446P (WT)-GCKR Treg and Tconv
cells, in further support of a key role of increased GCK availability
in enhanced 446L-GCKR Treg cell motility.
Collectively these observations suggest that GCK contributes
to human Treg cell migration.ImmuDISCUSSION
In this study we have investigated the
metabolic pathways that sustainmigration
of thymic Treg cells and how these path-
ways become engaged by pro-migratory
signals.
Our data indicate that migratory stimuli
induce metabolic reprogramming of Treg
cells toward aerobic glycolysis. However,
while induction of the glycolytic pathwayin dividing Treg lymphocytes relies upon mTORC1 activity
(Gerriets et al., 2016; Procaccini et al., 2010), activation of glucose
metabolism inducedbypro-migratorystimuli occursviamTORC2.
The molecular mechanism for the selective engagement of
mTORC2 for the induction of motility-associated glycolysis in
Treg cells remains unclear. Physiologically, Treg cells display
high activity of rapamycin-sensitive mTOR phosphorylation,
which is transiently inhibited by environmental stimuli to allow
their proliferation in vivo (Procaccini et al., 2010). A simplistic
explanation is that constitutively high mTORC1 activation
might limit its availability for additional signals. Thus, glycol-
ysis-activating stimuli in non-proliferating Treg cells may be re-
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Figure 7. Treg Cells Bearing a Loss-of-Function GCKR Allele Display Enhanced Motility
(A) Cell number/mL of Treg cells (CD4+CD25hiCD127lo) in carriers of the allele P446L compared to individuals carrying the WT allele (P446).
(B) Dot plots representative of 25 individuals analyzed.
(legend continued on next page)
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Consistent with this hypothesis, mTORC2 regulates the glyco-
lytic flux by fully activating AKT and controlling c-Myc expression
which in turn regulate the transcription of genes that control
glucose transport and glycolysis, including GLUT1 and HKII
(Masui et al., 2014). Finally, mTORC2 is known to mediate cyto-
skeleton reorganization (Cybulski and Hall, 2009) and substantial
evidence suggests that its activation requires PI3K activity
(Boulbes et al., 2010; Gan et al., 2011), but its ability to promote
cell migration via modulation of metabolic pathways has not
previously been described.
The dichotomy between regulation of glycolysis during Treg
cell proliferation and migration is also reflected in the enzymatic
machinery engaged for these cellular responses. Metabolic
reprogramming following antigen activation of conventional
T cell involves a substantial increase of hexokinase activity,
which is dependent on a transcriptional switch in HK isozyme
expression from HKI to HKII, which has higher affinity for
glucose (Bosca et al., 1988; Marjanovic et al., 1990; Wang
et al., 2011). In addition—and as a likely consequence of
mTORC2 activation—pro-migratory signals substantially
enhance GCK expression. In line with the non-redundant role
of mTORC2 in the metabolic regulation of motility, GKC has
been shown to be one of the main targets downstream of
mTORC2-mediated signaling in the liver (Hagiwara et al., 2012).
We have also provided evidence that this pathway might be
operational in the human immune system. The number of
circulating Treg cells was decreased in carriers of a GCKR
loss-of-function variant and mutant Treg cells display enhanced
motility, suggesting increased localization in tissues. Impor-
tantly, migration of Tconv cells is not affected by loss of GCKR
inhibition and increased GCK activity. The impact of enhanced
Treg cell trafficking on immune responses in these individuals
will require further investigation.
The physiological significance of preferential utilization of GCK
by migrating Treg cells remains to be defined by the use of mice
with T cell-specific GCK deficiency. Unlike other hexokinases,
GCK has a much lower affinity for glucose, which is within the
physiological plasma glucose range (S0.5 z7 mM) and is less
susceptible to inhibition by the glycolysis metabolite glucose
6-phosphate (Lenzen, 2014). The use of GCK by Treg cells might
explain the previous report of a delayed polarization rate of Treg
cells, compared to Tconv cells, in response to CD28 stimulation
(M€uller et al., 2008). CD28-stimulated Treg cells undergo early
and late waves of migration, which might reflect the posttran-
scriptional and transcriptional increase in GCK expression,
which we observed. GCK—which is not inhibited by glycolysis
metabolites—might also maintain the glycolytic flux and survival
in chronic inflammatory sites rich of inhibitory glycolysis metab-
olites, giving Treg cells an advantage over Tconv cells. In such
environments, Tconv cells tend to become hyporesponsive
and lose their function as a consequence, for example, of expo-(C–E)CD4+ lymphocyte subpopulations, defined as naive (CD45RA+), centralmemo
the two study populations.
(F and G) Migratory responses of Treg (F) and Tconv (G) cells from eight P446L-G
were measured by bare-filter 5 mm diameter transwells.
(H and I) The percentage of T cells expressing CCR7, receptor for the chemokine
(n = 8) and WT-GCKR (n = 8) subjects are shown.
*p < 0.05. Please see also Figure S7.sure to lactate (Haas et al., 2015). Alternatively, or in addition,
dependency on low-affinity GCK might promote retention of
Treg cells in glucose-depleted tissues such as tumors.
During immune responses, the ability of CD28 and CTLA-4 to
function as a metabolic switch might at least in part explain their
opposing effects on T cell division and function. For example,
transient CTLA-4 expression following activation might serve to
shut down glycolysis, thus supporting reprogramming of long-
lived memory CD8+ T cells to FAO (O’Sullivan et al., 2014),
thus promoting the contraction phase of T cell responses and
maintaining homeostasis by favoring the induction of anergy
(Zheng et al., 2009).
While the functional effects of CTLA-4 in the regulation of
effector immunity are well established, the contribution of
CTLA-4 to Treg cell function is not completely understood.
CTLA-4-deficient mice display normal numbers of Treg lympho-
cytes, which however appear to be defective in their suppressive
function in vivo (Wing et al., 2008) but not in vitro (Tang et al.,
2004). Our observations suggest that, by antagonizing CD28-
induced migratory signals, CTLA-4 might be required for tissue
retention rather than for Treg cell suppressive activity.
Impaired migration of Cd28Y170F Treg cells in response to
activation of innate immunity also indicates that CD28 signals
instruct their mobilization and redistribution from lymphoid
tissue – where CD28 engagement is likely to take place
during interaction with activated DCs - to the blood stream.
CD28-induced pro-migratory signals might dominate in the
absence of cognate interactions thus supporting Treg cell
recirculation. In contrast, transient upregulation of CTLA-4
by antigen-activation may reduce their motility leading to
retention within tissues.
In summary, this study defines a pathway for the metabolic
regulation of motility and migration induced in Treg cells by
pro-migratory stimuli. The apparent selectivity of this pathway
in the regulation of motility of both murine and human Treg cells
suggest that it might be possible to selectively manipulate traf-
ficking of distinct lymphocyte subsets by targeting different
glycolytic enzymes. Further, as the signaling mediators involved
in the metabolic reprogramming of proliferating Treg cells are
distinct from those regulating motility, selective targeting of
these enzymes might allow the modulation of distinct functions
in therapeutic settings.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
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s CCL19 and CCL 21 used in the migration assays, from P446L-GCKR carriers
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High-Capacity RNA-to-cDNA Kit Life Technologies, 4387406
TaqMan human L 750 uL
80X – assay ID: C___2862880_1_
Applied Biosystem 4351374
TaqMan MasterMix 50 ML Applied Biosystem 4371357
4–20% Mini-PROTEAN TGX
Precast Protein Gels
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Recombinant Mouse ICAM-1-Fc Chimera Biolegend 553004
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Recombinant human Exodus-2 (CCL21) Peprotech 300-35
Recombinat human IL-2 Peprotech 200-02
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CD4+CD25+ Treg cells This paper NA
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CD4+ effector T primary cells This paper NA
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C57BL/6 mice The Jackson laboratory 000664
CBA/Ca mice The Jackson laboratory 000654
BALB/c mice The Jackson laboratory 000651
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Dr B Malissen NA
Cd28Y170F Dr Klaus Okkenhaug (Okkenhaug et al., 2001)
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R:TGTGGCCACCGTGTCATTC
this paper NA
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R:CGTCACATTTCGGAGCCAGA
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R:TTAATGGTCAGAAGCCCGGT
this paper NA
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this paper NA
GAPDH: F:AGAACGGGAAGCTTGTCATCA;
R:GACCTTGCCCACAGCCTTG
this paper NA
CCR4: F:TGGTGGAGCTTGAAGTCCTT;
R:GGACATGTCAGCCGAGTAGA
this paper NA
CCR7: F:GGGCTGGTGATACTGACGTA;
R:ACACAGGTAGACGCCAAAGA
this paper NA
CD103: F:GGGTCCTACTTTGGCTCTGT;
R:GTGTGTGTGCCAAGGAGAAG
this paper NA
CD62L: F:GGGAACGAGACTCTGGGAAA;
R:ACCACATACTGACACTGGGG
this paper NA
CD69: F:AAGGACCATGGCACCAGTAT;
R:AGGTAGCAACATGGTGGTCA
this paper NA
CXCR3: F:GGGGTCTCTGTCTGCTCTTT;
R:CCTCATAGCTCGAAAACGCC
this paper NA
CD11a: F:TCCGGAAAGTGGAGATGC T;
R:GAAGTCTTCCCAGGAGCTGT
this paper NA
CD49d: F:AGCCGTTGGTGCATTTCAAT;
R:TGTAGCCTGGGACCTCTTTG
this paper NA
Recombinant DNA
pLKO.1 target gene set Gck Sigma TRCN0000012401
pLKO.1 target gene set Raptor Sigma TRCN0000077472
pLKO.1 – scramble shRNA Addgene Plasmid #1864
pLKO.1 target gene set Rictor Sigma TRCN0000123394
pMD2.G Addgene Plasmid #12259
pRSV-Rev Addgene Plasmid #12253
pMDLg/pRRE Addgene Plasmid #12251
Software and Algorithms
Graphpad prism Graphpad http://www.graphpad.com
SPSS version 21 IBM Corporation https://www.ibm.com/software/
it/analytics/spss/
Flow Jo_v10 FlowJo http://www.flowjo.com/
Microscopy Imaging software AxioVision Rel.4.8 http://www.zeiss.com
ImageJ ImageJ https://imagej.nih.gov
Confocal microscopy Leica LAS software NA
Adobe Phothoshop Adobe systems NA
NovoExpress Acea Bioscience, Inc. https://aceabio.com/products/novocyte/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Federica Marelli-
Berg (f.marelli-berg@qmul.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethical statement
Human blood was obtained from healthy donors according to ethical approval from the Universita` degli Studi di Milano (Cholesterol
and Health: Education, Control and Knowledge – Studio CHECK [SEFAP/Pr.0003] – reference number Fa-04-Feb-01). All in vivo
experiments were conducted with strict adherence to the Home Office guidelines (PPL 70/7443) following approval by the Queen
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Mice
All mice used in the experiments of this study were 7-11 weeks. C57BL/6, BALB/c and CBA/Ca mice were purchased from Charles
River (UK). The Foxp3-GFP (Foxp3-IRES-EGFP) genetically targeted mice on the C57BL/6 background were kindly provided by Dr B
Malissen (Centre d’Immunologie de Marseille-Luminy, Marseille, France). The Cd28Y170F genetically targeted mice on the C57BL/6
background were provided by Dr K Okkenhaug (Babraham Institute). Excised secondary lymphoid organs from 4week-oldCtla-4/
mice (of H-2u haplotype) were provided by Prof D Wraith (University of Birmingham).
Isolation of microvascular endothelial cells
Murine lungmicrovascular endothelial cells were isolated as previously described (Marelli-Berg et al., 2000). Mouse lungs were diced
into 2-3mm3 blocks, washed in phosphate buffered saline (PBS; Sigma-Aldrich, Cat# D8537) and digested in a solution containing
0.5mg/ml Type IV Collagenase (Sigma, Cat# C5138) for 30minutes in a humidified incubator maintained at 37C. A 70mmcell strainer
(Fisher scientific, Cat# 22363548) was then used to remove undigested tissuewhile the digested tissuewas collected and centrifuged
at low rpm (< 250 g). The supernatant was aspirated and further digested in trypsin/ (EDTA) (GIBCO,Cat# E7889) at 37C for 5minutes
to create a uniform cell suspension. The cell suspension was then washed with PBS at 300 g and resuspended in DMEM (GIBCO,
Cat# 11966-025) containing 10% FBS (Seralab, Cat# A210009). The cells were then seeded in 2% gelatinated (Sigma-Aldrich,
Cat# 1393) 25 cm2 culture flasks (Helena biosciences, Cat# 90026) for 24 hours. After 24 hours, non-adherent cells were removed
by washing with warm PBS and complete EC medium (mentioned below) was added to the culture.
EC culture
EC medium consisted of Dulbecco’s Modified Eagle media (DMEM, GIBCO, Cat# 41966-052) supplemented with 2 mM glutamine
(GIBCO, Cat# 250-30), 50 IU/mL penicillin (GIBCO, Cat# 15140-122), 50 mg/mL streptomycin (GIBCO, Cat# 15140-122), 50 mM
2-Mercaptoethanol (2-ME) (GIBCO, Cat# 31350-010), 1mM sodium pyruvate (GIBCO, Cat# 11360-039), 20mM N-2-hydroxyethylpi-
perazine-N’-2-ethane sulfonic acid (HEPES) (GIBCO, Cat# 15630-056), 1% non-essential amino acids (GIBCO, Cat# 11140-050),
20% FCS and 150 mg/ml EC growth supplement (Sigma-Aldrich, Cat# E0760). Medium was replaced every 48 hours. When
confluent, cells were detached with trypsin/EDTA (GIBCO, Cat# T4049) and passaged.
For functional assays, ECs were used between passages 2 and 8 and treated with 600 U/mL murine IFN-g (PeproTech,
Cat# 315-05) for 48 to 72 hours prior to use in experiments.
Isolation of bone marrow-derived Dendritic Cells (BMDCs)
Bone marrow(BM)-derived DCs were obtained fromWT BALB/c (H2-d) mice. Femurs and tibias from 7–to-10-week-old female mice
were removed and BM cells were flushed out with PBS using a 27-gauge needle (Becton Dickinson, Cat# 302200). Red blood cells
were lysed from the cell suspension with lysis buffer (Sigma-Aldrich, Cat# R7757). BM cells (5x106) were seeded per well in a 6 well
plate (Helena bioscience, Cat# 92006) in DC medium as described below.
Culture of Dendritic cells
Bone marrow-derived dendritic cells were cultured in RPMI 1640 medium (GIBCO, Cat# 21875-034) supplemented with 10% FCS,
2mM glutamine, 50 IU/mL penicillin, 50 mg/mL streptomycin, 50 mM 2-ME and 2% murine granulocyte-macrophage colony stimu-
lating factor (GM-CSF) obtained from the supernatant of the GMCSF hybridoma (gift from Dr. Jian-Guo Chai, Imperial College,
London, UK). Cells were cultured at 37C in the presence of 5%CO2. On days 3 and 5, fresh culturemediumwas added to the plates.
For Treg-DC cell co-cultures, immature BMDCs were collected and used on day 6 of culture. For functional assays, immature DCs
were matured overnight with 100ng/ml lipopolysaccharide (LPS) (Invivogen, Cat# tlrl-3pelps) and were used between day 7-10 post-
isolation.
Culture of H2-d allospecific Treg cells
CD4+CD25+ Treg cells were isolated from spleen and lymph nodes using Dynabeads FlowCompMouse CD4+CD25+ Treg Cells Kit
(Invitrogen Dynal, Cat#11463D). For extremely high purity of Treg cells (> 99%), CD4+CD25+Foxp3+ cells were obtained from
Foxp3-GFP reporter mice through Fluorescence-activated Cell Sorting. For expansion, Treg cells isolated from C57BL/6 (H2-b)
mice were stimulated weekly with either irradiated or mytomycin C (Sigma-Aldrich, Cat# M4287)-inactivated immature BALB/
c-derived (H2-d) DCs at a ratio of 5:1 (Treg:DC) (Fu et al., 2014). The co-cultures were maintained in complete T cell medium sup-
plemented with 10U/ml IL-2. Cells were harvested and seeded at an optimal density of 1.5x106 Treg cells per well of a 24-well tissue
culture (Helena bioscience, Cat# 92024) plate each week. The percentage of CD4+Foxp3+ cells after two weeks of culture was
greater than 95%. For use in functional assays, Treg cells were used 6-8 days after stimulation.
Antibody-mediated T cell activation
Activated T cells were obtained by polyclonal stimulation of LN cells with plate-bound anti-CD3 (1 mg/ml, eBiosciences,
Cat# 16-0032-85) and plate-bound anti-CD28 (5 mg/ml, eBiosciences, Cat# 16-0281-86) in complete T cell medium supplemented
with 20 U/ml recombinant IL-2 (Roche, West Sussex, UK) for 7 days at 37C. Antibody coating of tissue culture plates was performed
by incubating antibodies in 200 mL of Tris buffer (pH 8.5) at 37C for 1 hour.e5 Immunity 47, 875–889.e1–e10, November 21, 2017
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Lymphocyte trans-endothelial migration and chemotaxis assays
Primary microvascular ECs treated with IFN-g for 48–72 h were seeded (3x104) and cultured on 2% gelatin-coated Transwell inserts
(diameter, 6.5 mm) containing 3-mm pore size (Costar, Cat# CLS3472-48EA) polycarbonate membranes in EC medium for 16 h to
from a monolayer. T cells (5x105) resuspended in migration medium (RPMI 1640 supplemented with 2% fetal bovine serum) were
added to each insert and left to migrate through the monolayer; the well volume was also replaced with fresh migration media.
The number of migrated T cells was determined by a hemocytometer counting of the cells present in the well media at different
time points over a 24-h period. To measure chemotaxis, T cells were seeded onto Transwell bare-filter tissue culture well inserts
(diameter, 6.5 mm) with 5- or 3-mm pore size (Costar, Cat# CLS3421-48EA) polycarbonate membranes and chemokine-containing
migration medium was placed in the bottom of the well. The number of migrated cells was determined by a hemocytometer.
Assessment of Treg cell apoptosis
Apoptosis of Treg cells treated with increasing doses of TNFa (5 and 50 ng/ml, PeproTech,INC, Cat# 315-01A) or heat wasmeasured
using Annexin V-FITC Apoptosis Detection Kit (Abcam, Cat#ab14085). Cells were subsequently analyzed using flow cytometry.
Induction of CD28, CTLA-4 and LFA-1 signaling
Induction of CD28 and CTLA-4 signaling by antibody stimulation was performed as previously described (Schneider et al., 2005;
Wells et al., 2001). To induce co-stimulatory signals via CD28 and CTLA-4 co-receptors for functional assay, cells were incubated
with antibodies targeting the functional domains of the co-receptors. To induce CD28 signaling, T cells were treated with a mixture
of hamster anti-mouse CD28 (5 mg/5x106 cells) (clone: 37.52, Bio-Rad, Cat# MCA1363) and goat anti-hamster immunoglobulin (Ig)
(2.5 mg/5x106 cells) (Bio-Rad, Cat# STAR104) for different time points as described in each figure separately. Similarly, CTLA-4
signaling was achieved by incubating T cells with a mixture of hamster anti-mouse CTLA-4 (5 mg/5x106 cells) (clone: UC10-
4F10-11, Becton Dickinson, Cat# 553718), and goat anti-hamster immunoglobulin (Ig) (2.5 mg/5x106 cells) (Bio-Rad, Cat#
STAR104). A hamster IgG isotype control was used to observe any non-specific effects of the antibody stimulation (Bio-Rad,
Cat# MCA2356). To induce LFA-1 signaling, cells were incubated with 2 mg/5x106 cells recombinant mouse ICAM-1-human IgG
Fc chimeras (2 mg/ml, R&D Systems, Cat# 796-IC-050) or human IgG-Fc fragments (R&DSystems, Cat# 110-HG) as a control – either
plastic-bound or ligated with a mouse anti-human IgG (1 mg/ml, MK1A6, Bio-Rad Cat# MCA647G) - for different time points as
described in each figure separately. T cells were washed in PBS prior to use in the experiments.
Fluorescent labeling of viable T cells
For labeling T cells with fluorescent probes, T cells were washed with PBS, counted and resuspended in PBS at a final concentration
of 107/ml. If necessary, dead cells were removed using density gradient centrifugation with Ficoll-Paque prior to re-suspension.
Labeling of T cells with PKH26 (Sigma-Aldrich, Cat# PKH26GL-1KT), a cell linker dye for cell membranes was performed using
manufacturer instructions. PKH26 was added at a final concentration of 5mM, and the cells were incubated at room temperature
for 5 minutes. The reaction was inactivated by adding an equal volume of FBS to the cell suspension and the cells were washed
in PBS containing 10% FBS for 10 minutes. Labeling of T cells with succinimidyl ester dyes CFSE (Invitrogen, Cat# C1157) or
DDAO-SE (Invitrogen, Cat# C34553) was performed by incubating the T cells in PBS containing final concentration of 3.3 mM
CFSE or 1.3 mM DDAO-SE for 10-15 minutes at room temperature. The reaction was terminated by adding equal volume FBS
and the cells were then washed with PBS containing 10% FBS for 10 minutes.
T cell recruitment in the peritoneum
To observe in vivo recruitment of T cells we used a previously described model (Mirenda et al., 2007). Either PKH26 or CFSE or
DDAO-SE-labeled T cells (107) were injected intravenously (i.v.) into mice that hd received IFN-g (600U) via intraperitoneal injection
(i.p.) 48 to 72 hours earlier. Labeled T cells recovered via peritoneal lavage were analyzed 16 hours later using flow cytometry. In
addition, localization of Treg cells to the spleen, where entry occurs in a passive manner, was analyzed to ensure that similar
numbers/proportion of labeled cells were injected or co-injected in all recipients (internal control).
Zymosan-induced peritonitis
On day 0, mice were given intraperitoneal injections of Zymosan (1 mg/mouse, Cat# 4250 SIGMA) in sterile saline solution to induce
peritonitis. Mice were sacrificed 72 hours post-injection and tissue samples obtained for flow cytometry analysis.
Widefield deconvolution fluorescence microscopy
Tissues samples were excised, embedded in Optimal Cutting Temperature compound (OCT; Thermo Fisher Scientific,
Cat# 12678646), snap-frozen and stored until analysis. Frozen tissue sections were laid onto Polysine coated microscope slides
(VWR International, Cat# 47100), air-dried and then fixed with ice cold acetone (Sigma, Cat# 534064) for 10 min. Tissue sections
werewashed in PBS, blockedwith serum for 3 hours and stained usingmentioned primary antibodies at 4C for 24 h. Excess antibody
was washed away with PBS and tissues were stained with indicated secondary antibodies along with DAPI (4’,6-diamidino-2-phenyl-
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Antifade Reagent (Invitrogen/Life Technologies, Cat# P36930) and visualized using a Zeiss Z1 fluorescence microscope (Carl Zeiss,
UK) equipped with an AxioCam MRm Cooled monochrome digital camera and an Apotome 2 Imaging unit. Images were acquired
using a Plan Apochromat 20x/0.8 NA objective and Axiovision software version 4.8 (Carl Zeiss, UK). For staining, Treg cells were
cultured in R10 medium and fixed with 3.7% formaldehyde. After fixing, they were stained with anti- GCK, anti-Na,K-ATPase
and 1 ng/ml tetramethyl rhodamine B isothiocyanate–conjugated phalloidin (Sigma-Aldrich Cat# P1951) for 30 min at 37C and
respectively. This was followed by secondary antibodies Alexa Fluor 555 goat anti-mouse Ig (Biolegend Cat# 405324) and FITC
Donkey anti-rabbit IgG (minimal x-reactivity) Antibody (Biolegend 406403). Coverslips were extensively washed, air-dried, and
mounted in Vectorshield mounting medium for fluorescence with DAPI (Vector Laboratories Cat# z0603) on glass slides.
Confocal microscopy
Cells were allowed to adhere onto poly-L-lysine coated coverslips and fixed in 4% paraformaldehyde (Thermo Fisher Scientific,
Cat# 28906) for 5-10 minutes at room temperature. Where mentioned, permeabilization was carried out using 0.2% Triton X-100
(Sigma-Aldrich, Cat# X100-500ML) in PBS for 5 minutes. Cells were then washed in PBS, blocked in blocking buffer (PBS containing
0.1% Fish skin gelatin; Sigma-Aldrich, Cat# G7765) and 1% serum of the species giving rise to secondary antibodies) for 3-6 hours
and then stained with appropriate primary antibodies at 4C for 16 hours in the dark. Following staining, cells were washed again and
stained with corresponding secondary antibodies and DAPI for 30 minutes at room temperature. After multiple PBS washes cover-
slips were mounted onto slides using ProLong Gold Antifade (Invitrogen/Life Technologies, Cat# P36930) and then examined using a
Leica SP5 confocal microscope equipped with a 633 1.4 NA objective. Confocal images and Z stacks were acquired and analyzed
by Leica LAS software. Repositioning of scale bars and image layouts were prepared using Adobe Photoshop (Adobe Systems). All
images in a group were treated equally.
In vitro 6-NBDG uptake assay
Freshly isolated or cultured T cells were washed in PBS and resuspended in glucose free T cell medium (GIBCO, Cat# 11879-020)
containing various mentioned signaling antibodies and incubated for 45 minutes at 37C with 5% CO2. A final concentration
of 400 mM 6-NBDG (Life Technologies, Cat# N23106) in glucose free T cell medium was then added to the cells and the cells
were further incubated for an additional 10-15 minutes. Finally, the cells were washed twice with warm PBS and resuspended in
flow cytometry buffer and placed on ice. Immediate analysis was performed using flow cytometry to observe fluorescence uptake
by the T cells.
In vitro 6-NBDG uptake assay (human studies)
Freshly isolated CD3+ T cells were washed in PBS and cultured 106/mL in R2 (RPMI 1640 supplemented with 2% fetal bovine serum)
with recombinant CCL19 and CCL21 (200 ng/mL - Peprotech Cat#300-29B and 300-35) at 37C with 5% CO2. A final concentration
of 400 mM 6-NBDG (Life Technologies, Cat# N23106) was added to the cells and incubated for 0, 15, 30 and 60 minutes. Finally, the
cells were washed twice with warm PBS, stained for CD4+ T cells and Treg and placed on ice. Immediate analysis was performed
using flow cytometry to observe fluorescence uptake by Treg cells.
In vivo 6-NBDG uptake assay
Tomeasure glucose uptake activity of T cells in vivo, PKH26 labeled T cells (3x106) were injected i.p. into mice. A second i.p. injection
of 6NBDG (400 mM in Sterile water) was given to the mice immediately afterward. After a 1-hour period, the mice were sacrificed and
the mesenteric (draining) lymph nodes and spleen collected for analysis by flow cytometry. Widefield microscopy of the peritoneal
membranes was performed to observe influx of labeled T cells into the peritoneal membrane. PKH26+ T cells infiltrating the mem-
branes were further analyzed for 6NBDG uptake (green fluorescence) using image analysis software ImageJ. The number of labeled
cells in 10x magnification field views images was counted manually to determine differences in T cell infiltration.
Measurement of ECAR and OCR
Real time bioenergetics analysis of extracellular acidification rates (ECAR) and oxygen consumption rates (OCR) of T cells subjected
to antibody stimulation was performed using the XF analyzer (Seahorse biosciences). T cells were cultured in serum free, unbuffered
XF assay medium (Seahorse biosciences, Cat# 102365-100) for 1 hour. The cells were then seeded (6x105/well) into the seahorse
XF24 cell plates for analysis. Perturbation profiling of the use of metabolic pathways by T cells was achieved by the addition of
oligomycin (1 mM), FCCP (1 mM), Antimycin A (1 mM), rotenone (1 mM), D-glucose (10mM), 2-Deoxy-D-glucose (2DG, 50mM; all
fromSeahorse biosciences, Cat# 103020-100 and 103015-100). Experiments with the Seahorse systemwere donewith the following
assay conditions: 2 min mixture; 2 minutes wait; and 4–5 min measurement. Metabolic parameters were calculated. Experiments
were done in at least triplicate wells.
Surface staining
For surface staining, cells were resuspended (107/ml) and stained with flurochrome- conjugated antibodies in 100 mL of Flow cytom-
etry buffer made of PBS containing 0.1% sodium azide (Sigma-Aldrich, Cat# S2002-25G) and 1% FBS at 4C for 30 minutes. CCR7
antibody staining was performed at 37C for 30 mins. Optimal antibody concentrations for staining were calculated based on
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immediately. Alternatively, for delayed analysis, cells were fixed in fixation buffer (flow cytometry buffer containing 1% Formalde-
hyde, Sigma-Aldrich, Cat# 15,812-7)) for 30 minutes at 4C, washed and stored in flow cytometry buffer at 4C. The table below
indicates the fluorescent antibodies that were used in this study.
Intracellular staining
For intracellular Foxp3 staining, eBioscience Anti-Mouse/Rat Foxp3 Staining Set APC (clone FJK-16S, Thermo Fisher Scientific
Cat# 17-5773-82) kit was used. Cells were resuspended (107/ml) and stained with surface antigens as mentioned above and then
fixed/permeabilized for 30 minutes at 4C using Fixation/Permeabilization working solution made from mixing 1 part of the
fixation/permebilization concentrate (eBioscience, Cat# 00-5123) to 3 parts of the fixation/permebilization diluent (eBioscience,
Cat# 00-5223). The cells were then washed twice in 1X permeabilization buffer (eBioscience, Cat# 00-8333) and stained with
fluorochrome conjugated-Foxp3 antibody in 1x permeabilization buffer for 30 minutes at 4C. A final wash with 1x permeabilization
buffer was performed and the cells were then centrifuged and resuspended in 200ul of flow cytometry buffer. For T cell proliferation
studies, Treg cells were stimulated with immature BALB/c DCs. 3 hours later, Treg cells were fixed and permeabilized with ice cold
70% ethanol before staining for proliferating cell nuclear antigen (PCNA, clone PC10, BioLegend Cat# 307908).
In vitro AKT phosphorylation (human studies)
Freshly isolated concentional CD4+CD25- T cells (Tconv) andCD4+CD25+ (Treg) T cells were washed in PBS and cultured 53 106/mL
in R2 (RPMI 1640 supplemented with 2% fetal bovine serum). 0.5 3 106 CD4+CD25- (Tconv) and CD4+CD25+ (Treg) were plated
in 96-well plate and stimulated for 15 minutes or not with chemokines CCL19 and CCL21 (1 mg/mL - Peprotech Cat# 300-29B
and 300-35) at 37C with 5% CO2. Cells were immediately fixed to stop stimulation with 2% formaldehyde for 10 minutes at RT in
the dark. Cells were washed and resuspended in 100% ice-cold methanol and incubated for 30 minutes on ice. Subsequently, cells
were washed twice with PBS 2%FBS and stained for pAKT-s473 (eBioscience, Cat# 17-9715-41) for 30 minutes at 4C in the dark.
Cells were washed, resuspended in PBS 2%FBS and immediately analyzed by flow cytometry.
Western Blotting and coimmunoprecipitation
Whole-cell lysates were lysed in Nonidet P-40 lysis buffer [50 mM HEPES (pH 8.0), 350 mM NaCl, 1% Nonidet P-40, 1 mM EDTA,
1 mM Na3VO4, 1 mM NaF, 20 mM glycerol-2-phosphate, 1 mM PMSF, 1 mM DTT, 10 mg/mL aprotinin, 10 mg/mL leupeptin, and
protease inhibitor cocktail (Roche Cat# 11836145001). Equivalent amounts of protein as determined by standard Bradford assay
(Bio-Rad Cat# 5000001) were separated by SDS/PAGE and transferred to nitrocellulose membrane (GE Healthcare Life Sciences
Cat# 10600002). Membranes were blocked for 2 h at room temperature in 5% milk/TBS-Tween 20 (Sigma Cat# P1379) and were
incubated overnight at 4C with the primary antibodies listed below. HRP-conjugated secondary antibody (1:5000; Amersham
Bioscience Cat# NA934) was subsequently added. Films were then developed. The intensity of the bands was quantified using
ImageJ (NIH). For coimmunoprecipitation experiments, cell extracts were prepared in RIPA buffer. 250 mg of total protein extract
was first precleared with Protein G–Agarose beads (Sigma Cat# P3296) for 1 hour at 4C, incubated with 5 mg of anti-GCK Ab (Santa
Cruz Biotechnology Cat# SC7908) overnight at 4C and then with Protein G beads for another 16hrs at 4C. The final pellet was
resuspended in 10 mM Tris HCl, pH 7.4, supplemented with 1 mM PMSF and analyzed by western blot for B actin (Santa Cruz
Cat# SC161).
Quantitative real time PCR (qRT-PCR)
Tissues were harvested and stored in RNA-later (QIAGEN Cat# 76104) at –80C until processing. RNA was purified using Trizol
reagent (Life Technologies Cat# 15596) according to the manufacturer’s instructions and assessed for quality and quantity using
absorption measurements. Reverse transcription was performed according to the manufacturer’s instruction (Applied Biosystems
Cat# 4374966). Gene expression analysis was done using SYBR Green Supermix (Biorad Cat# 1725120) in CFX connect light cycler
(Biorad Cat# 1855200). Expression was calculated using the DDCt method (Livak and Schmittgen, 2001) and normalized to a house-
keeping gene (GAPDH). Primers for qPCR were designed with the help of online tools (Primer 3Plus) using at least one exon junction-
binding site per primer pair. The thermal cycling profile for amplification was 95C for 10 min, followed by 40 cycles of 95C for 15 s
and 54C for 1 min. Amplification was at 95C for 10 min, followed by 40 cycles of 95C for 15 s and 60C for 1 min. To ensure the
amplification specificity, the melting curve programwas set as follows: 95C for 15 s, 60C for 1 min, and 95C for 15 s, right after the
PCR cycles. Experiments were done in triplicates.
Lentivirus Preparation for Gene Silencing
HEK293T cells were grown in 10cm cell-culture dishes to 70% confluence and were transfected with the above plasmids using the
calcium phosphate method. The supernatant was harvested 48 and 72 h after transfection and was concentrated 100-fold in an
ultracentrifuge. Aliquots were stored at 80C. For transduction of Treg cells, cells were seeded in six-well plates and cultured in
DMEM to 60%–70% confluence. Lentivirus was added to the cells in the presence of 5 mg/mL Polybrene (Sigma-Aldrich
Cat# 107689), and the six-well plate was centrifuged at 2,300 rpm for 90 min at room temperature, followed by 8 h incubation
at 37C with 5% CO2. Virus was removed 24 h later; T cells were washed twice with PBS and incubated for 24 h in complete
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Study population
The Progressione della Lesione Intimale Carotidea (PLIC) Study (a sub-study of the CHECK study) is a large survey of the general
population of the northern area of Milan (n = 2.606) (Baragetti et al., 2015; Lorenz et al., 2012; Norata et al., 2009; Norata et al.,
2006), followed at the Center for the Study of Atherosclerosis, Bassini Hospital (Cinisello Balsamo, Milan, Italy). The Study was
approved by the Scientific Committee of the Universita` degli Studi di Milano (‘‘Cholesterol and Health: Education, Control and Knwo-
ledge – Studio CHECK ((SEFAP/Pr.0003) – reference number Fa-04-Feb-01) in Febraury 4th 2001. An informed consent was obtained
by subjects in accordance with the Declaration of Helsinki.
Genomic DNA was extracted using Flexigene DNA kit (QIAGEN, Milan, Italy). Genotyping for the p.Leu446Pro GCKR missense
mutation was available on the entire population, using TaqMan allelic discrimination test. The experimental analysis was conducted
on a subgroup of 16 subjects, eight Leu 446-GCKR and eight Pro 446-GCKR matched for age and gender.
Blood surface and intracellular staining (human studies)
For surface staining, 100mL of whole blood were stained with flurochrome-conjugated antibodies in 50 mL of MACS buffer made of
PBS containing, 2% FBS and 2mM EDTA at RT (room temperature) for 30 minutes in the dark. Optimal antibody concentrations for
staining were calculated based on manufacturer instructions. Following staining, red blood cells were lysed with 2 mL of 1-step fix/
lyse solution (eBioscience, Cat#00-5333-54) for 20 minutes at RT, washed and resuspended with MACS buffer and analyzed
immediately.
Alternatively, for intracellular staining, peripheral bloodmononuclear cell (PBMCs) were isolated (as described below) and used for
the staining (1-step fix/lyse solution is incompatible with some intracellular stainings). Cells were resuspended (107/mL) and stained in
in 50 mL of MACS buffer with surface antigens. For intracellular Foxp3 and Ki67 staining, eBioscience Anti-Mouse/Rat Foxp3 Staining
Kit was used (Cat#77-5775-40). Cells were fixed/permeabilized ON at 4C using Fixation/Permeabilization working solution made
from mixing 1 part of the fixation/permebilization concentrate to 3 parts of the fixation/permebilization diluent. Cells were then
washed twice in 1X permeabilization buffer and stained with fluorochrome conjugated-Foxp3 and –Ki67 antibodies in 1x permeabi-
lization buffer for 30 minutes at 4C. A final wash with 1x permeabilization buffer was performed and the cells were then centrifuged
and resuspended in 200 mL of MACS buffer. The table above indicates the fluorescent antibodies that were used in this study.
PBMC isolation and CD4+CD25+ Treg cell purification (human studies)
For each subject, 30mLof blood (supplementedwith EDTA)were split in two falconof 15mLand spin for 12minutes at 1000xg. Plasma
was discarded and the interface between plasma and red blood cells, enriched in leukocytes and platelets (buffy coat), was carefully
collected, diluted with cold PBS and stratified on 3 mL of Ficoll-PlaqueTM PREMIUM (GE-Healthcare, Cat#17-5442-03). After centri-
fugation of 35minutes at 250xg, PBMC layerwas carefully collected andwas 3 timeswith 10mLof cold PBS at 180xg for 12minutes to
get rid of platelets. PBMCwere counted and use for CD4+CD25+ Treg purification with CD4+CD25+ Regulatory T cell isolation kit, hu-
man (Miltenyi Biotec., Cat#130-09-301) according to manufacturer instructions. Purified CD4+CD25+ Treg or CD4+CD25- Tconv cell
were counted with a hemocytometer and used for migration and suppression assay.
Treg and Tconv cell migration assay (human studies)
300 mL of Treg and Tconv cells (1x105) of each subject were resuspended in migration medium (RPMI 1640 supplemented with 2%
fetal bovine serum) and cultured on Transwell inserts (diameter, 6.5 mm) with 5-mm pore size (Costar, Cat# CLS3421-48EA) polycar-
bonate membranes. Cells were left to migrate versus migration medium or chemokines CCL19 and CCL21 (200 ng/mL - Peprotech
Cat#300-29B and 300-35), placed in the bottom of the well, for 1, 2, 4 and 12 hours. The number of migrated cells was determined by
a hemocytometer and data expressed as percentage of migration compared to cultured cells.
Suppression assay (human studies)
CD4+CD25- Tconv cells were resuspended inMACSbuffer (107/mL) and labeledwith succinimidyl ester dyesCFSE (2mM- Invitrogen,
Cat# C1157) for 10minutes at RT in the dark. Cells were washed 3 times withMACS buffer and centrifuged at 360xg for 5minutes. 96
well-plate U-bottomwere coatedwith anti-humanCD3 purified antibody (5 mg/mL - eBioscience, Cat#14-0039-82) for 1 hour at 37C.
Tconv were resuspended (106/mL) in complete medium (RPMI 1640 supplemented with 10% FBS, 1mM Na-Pyruvate, 10mM
HEPES, 50 mM b-MeOH and pen/strep/glutamine) plus 50 U/mL of IL-2 (Peprotech; Cat#200-02) and 2 mg/mL of anti-human
CD28 purified antibody (eBioscience, Cat#14-0289-82) and (1x105/100 mL) were plated. CD4+CD25+ Treg cells were washed and
resuspended in complete medium and added to Tconv cells according to the following proportions (Tconv:Treg): 1:1, 1:0,5,
1:0,25 and 1:0 by performing serial dilution of Treg cells with complete medium in a 96-well plate. The plate was then spun 1 minute
at 120 g and incubated at 37C for 4 days. Cells were then collected and for each subject the percentage of proliferated cells in the
presence of Treg cells was compared to the condition of Tconv:Treg cells 1:0 (100% proliferation).
QUANTIFICATION AND STATISTICAL ANALYSIS
The qPCR data were analyzed using the delta delta CT method by taking the CT values of the genes of interest from the house
keeping gene following by normalization to the wild-type control sample. Results were done transported to prism before graphic
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Results are given as the mean per group ± SD. The data were analyzed using a two-tailed unpaired Student’s t test and Mann-
Whitney test. A p value of less than 0.05 was considered significant. Experimental datasets from the seahorse were analyzed using
one-way ANOVA with Bonferroni correction or Kruskal-Wallis with Dunn’s post-test to take into account of multiple comparisons.
Where indicated ‘n’ represent the number of biological replicates. Human data were analyzed by ANCOVA (Analysis of Co-Variances)
models between TT and CC genotypes of the rs1260326 GCKR polymorphisms (adjusting by age and gender). In supplemental table
variables are presented as mean (standard deviations, SD) if normally distributed or as median (Inter-Quartile Range, IQR) if non
normally distributed (Shapiro-Wilk test). t test to compare normally distributed variables and U-Mann Whitney for non-normally
distributed variables were performed (p values for each variables are reported; p less than 0.05 are significant). Grubb’s test for
outliers detection was performed for each variables.
For human results, data are reported as the mean per group ± SEM. The data were analyzed using a two-tailed unpaired Student’s
t test and Mann-Whitney test. A p value of less than 0.05 was considered significant.Immunity 47, 875–889.e1–e10, November 21, 2017 e10
